Galectin-3 testing: Validity of a novel automated assay in heart failure patients with reduced ejection fraction

Clinica Chimica Acta

Volumn 429, Issue , 2014, Pages 189-193

  Gruson, D ^a   Mancini, M ^a   Ahn, S A ^a   Rousseau, M F ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Biomarkers; BNP; Galectin 3; Heart failure; NT proBNP; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; PRO BRAIN NATRIURETIC PEPTIDE[1-108]; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; AUTOMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ANALYSIS; HEART EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; RISK ASSESSMENT; SYSTOLIC HEART FAILURE; VALIDITY;

BIOMARKERS; BNP; GALECTIN-3; HEART FAILURE; NT-PROBNP; PROGNOSIS;

ADULT; AUTOMATION; BLOOD CHEMICAL ANALYSIS; FEMALE; GALECTIN 3; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; STROKE VOLUME;

EID: 84891696028     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.12.017     Document Type: Article

References (27)

1. Braunwald E., Bristow M.R. Congestive heart failure: fifty years of progress. Circulation 2000, 102:IV14-IV23.
2. Yancy C.W., Jessup M., Bozkurt B., et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2013, 2013:10.
3. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992, 20:248-254.
4. Piano M.R., Prasun M. Neurohormone activation. Crit Care Nurs Clin North Am 2003, 15:413-421.
5. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol 2000, 35:569-582.
6. Emdin M., Vittorini S., Passino C., Clerico A. Old and new biomarkers of heart failure. Eur J Heart Fail 2009, 11:331-335.
7. Clerico A., Vittorini S., Passino C. Measurement of the pro-hormone of brain type natriuretic peptide (proBNP): methodological considerations and pathophysiological relevance. Clin Chem Lab Med 2011, 49:1949-1954.
8. Clerico A., Giannoni A., Vittorini S., Passino C. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol 2011, 301:H12-H20.
9. Prontera C., Storti S., Emdin M., et al. Comparison of a fully automated immunoassay with a point-of-care testing method for B-type natriuretic peptide. Clin Chem 2005, 51:1274-1276.
10. Hammerer-Lercher A., Halfinger B., Sarg B., et al. Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem 2008, 54:858-865.
11. Giuliani I., Rieunier F., Larue C., et al. Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clin Chem 2006, 52:1054-1061.
12. Richards A.M. Natriuretic peptides: update on peptide release, bioactivity, and clinical use. Hypertension 2007, 50:25-30.
13. de Boer R.A., Yu L., van Veldhuisen D.J. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010, 7:1-8.
14. Gruson D., Ko G. Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases?. Clin Biochem 2012, 45:719-726.
15. Seetharaman J., Kanigsberg A., Slaaby R., Leffler H., Barondes S.H., Rini J.M. X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-A resolution. J Biol Chem 1998, 273:13047-13052.
16. Cooper D.N., Barondes S.H. God must love galectins; he made so many of them. Glycobiology 1999, 9:979-984.
17. Lin Y.H., Lin L.Y., Wu Y.W., et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009, 409:96-99.
18. de Boer R.A., Voors A.A., Muntendam P., van Gilst W.H., van Veldhuisen D.J. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009, 11:811-817.
19. Lok D.J., Van Der Meer P., de la Porte P.W., et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010, 99:323-328.
20. Shah R.V., Chen-Tournoux A.A., Picard M.H., van Kimmenade R.R., Januzzi J.L. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010, 12:826-832.
21. van Kimmenade R.R., Januzzi J.L., Ellinor P.T., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006, %19;48:1217-1224.
22. Christenson R.H., Duh S.H., Wu A.H., et al. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin Biochem 2010, 43:683-690.
23. La'ulu S.L., Apple F.S., Murakami M.M., Ler R., Roberts W.L., Straseski J.A. Performance characteristics of the ARCHITECT galectin-3 assay. Clin Biochem 2013, 46:119-122.
24. Wu A.H., Smith A., Rame E., et al. Analytical assay characterization for 1-108 pro-B-type natriuretic peptide on the BioPlex 2200 analyzer. Clin Chim Acta 2009, 408:143-144.
25. de Boer R.A., Lok D.J., Jaarsma T., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011, 43:60-68.
26. Gruson D., Lepoutre T., Ahn S.A., Ketelslegers J.M., Rousseau M.F. Comparison between intact and bioactive parathyroid hormone assays in patients with severe heart failure. Clin Biochem 2013, 46:391-394.
27. Carrasco Sanchez F.J. Galectin-3-independent prognosis in heart failure. Clin Res Cardiol 2011, 100:183.